• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Melinda Magyari Discusses Data on Treating Pediatric MS

Video

Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, discusses the current body of data on treating pediatric multiple sclerosis (MS).

Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, discusses the current body of data on treating pediatric multiple sclerosis (MS).

Transcript

How good is our current body of data on treating pediatric MS?

Because there have not been randomized control trials, only a few of them in pediatric-onset MS, the current evidence is not very strong. Randomized controlled trials exclude patients younger than 18 years. So I would, and as you can see in my presentation, most of the patients have been treated with intramuscular interferons. So the body of evidence on that treatment is rather good. But we need more observational data. We need large cohorts, maybe to merge them. Because the data is there, we just have to provide evidence.

Related Videos
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Pierluigi Porcu, MD
Benjamin Chen, MD, PhD
Kimberly Westrich, MA, chief strategy officer, NPC
Erin Weber, MS
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Marla Black Morgan, MD, Phoebe Neurology Associates
Elizabeth Grush, MBA
Raj Chovatiya, MD, PhD, MSCI.
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.